Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of evolocumab on vascular function in atherosclerotic cardiovascular disease
2017-004129-33Phase 4Completed
- Sponsor
- Friedrich-Alexander University Erlangen-Nuremberg
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of evolocumab in atherosclerotic disease, sponsored by Friedrich-Alexander University Erlangen-Nuremberg. Started May 2018; status: completed.
02
Drugs
evolocumab
03
Conditions
atherosclerotic disease
Beyond the preview
Go deeper on 2017-004129-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004129-33.